1-2 of 2
Kiyoshi Ando
Close
Save search
Sort by
Journal Articles

Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study

Free
Clinical Trials & Observations
Won-Seog Kim, Noriko Fukuhara, Dok-Hyun Yoon, Kazuhito Yamamoto, Toshiki Uchida, Eiju Negoro, Koji Izutsu, Yasuhito Terui, Hideaki Nakajima, Kiyoshi Ando, Youko Suehiro, Hye Jin Kang, Po-Shen Ko, Fumiko Nagahama, Yusuke Sonehara, Hirokazu Nagai, Hwei-Fang Tien, Yok-Lam Kwong, Kensei Tobinai
Journal: Blood Advances
Blood Adv (2023) 7 (17): 4903–4912.
https://doi.org/10.1182/bloodadvances.2022008615
Published: 2023
Journal Articles

A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial

Free
Clinical Trials & Observations
Ken Ohmachi, Tomohiro Kinoshita, Kensei Tobinai, Gakuto Ogawa, Tomonori Mizutani, Nobuhiko Yamauchi, Noriko Fukuhara, Toshiki Uchida, Kazuhito Yamamoto, Kana Miyazaki, Norifumi Tsukamoto, Shinsuke Iida, Takahiko Utsumi, Isao Yoshida, Yoshitaka Imaizumi, Takashi Tokunaga, Shinichiro Yoshida, Yasufumi Masaki, Tohru Murayama, Yoshihiro Yakushijin, Youko Suehiro, Kisato Nosaka, Nobuaki Dobashi, Junya Kuroda, Yasushi Takamatsu, Dai Maruyama, Kiyoshi Ando, Kenichi Ishizawa, Michinori Ogura, Tadashi Yoshino, Tomomitsu Hotta, Kunihiro Tsukasaki, Hirokazu Nagai, the Japan Clinical Oncology Group
Journal: Blood Advances
Blood Adv (2021) 5 (4): 984–993.
https://doi.org/10.1182/bloodadvances.2020002567
Published: 2021
Includes: Supplemental data